Diabetic Neuropathy - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 114
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D3E08F5A71DEN
Leaflet:

Download PDF Leaflet

Diabetic Neuropathy - Pipeline Review, H2 2017
Diabetic Neuropathy - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 4, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy - Overview
Diabetic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Angelini Group
Apollo Endosurgery Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
Commence Bio Inc
Grifols SA
Grunenthal GmbH
Immune Pharmaceuticals Inc
Kineta Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Neuralstem Inc
NovaLead Pharma Pvt Ltd
Novaremed Ltd
Omeros Corp
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
ViroMed Co Ltd
Diabetic Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + triclocarban) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNV-222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cibinetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNV-2197944 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-32 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-8554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTA-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for CNS Disorders, Toxicology and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Diabetic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trazodone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Featured News & Press Releases
Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage
Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
Feb 07, 2008: EpiCept Announces Encouraging Results Of Phase II Trial For NP-1 Cream In Diabetic Peripheral Neuropathy
Dec 03, 2007: Patient Enrollment Gets Completed In Phase IIb Trial Of EpiCept NP-1 In Diabetic Peripheral Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Neuropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017
Diabetic Neuropathy - Pipeline by Angelini Group, H2 2017
Diabetic Neuropathy - Pipeline by Apollo Endosurgery Inc, H2 2017
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017
Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2017
Diabetic Neuropathy - Pipeline by Celgene Corp, H2 2017
Diabetic Neuropathy - Pipeline by Commence Bio Inc, H2 2017
Diabetic Neuropathy - Pipeline by Grifols SA, H2 2017
Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H2 2017
Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Diabetic Neuropathy - Pipeline by Kineta Inc, H2 2017
Diabetic Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017
Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2017
Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Diabetic Neuropathy - Pipeline by Neuralstem Inc, H2 2017
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017
Diabetic Neuropathy - Pipeline by Novaremed Ltd, H2 2017
Diabetic Neuropathy - Pipeline by Omeros Corp, H2 2017
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2017
Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2017
Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2017
Diabetic Neuropathy - Dormant Projects, H2 2017
Diabetic Neuropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Neuropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diabetic Neuropathy - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Neuropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Achelios Therapeutics Inc
Angelini Group
Apollo Endosurgery Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
Commence Bio Inc
Grifols SA
Grunenthal GmbH
Immune Pharmaceuticals Inc
Kineta Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Neuralstem Inc
NovaLead Pharma Pvt Ltd
Novaremed Ltd
Omeros Corp
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
ViroMed Co Ltd
Skip to top


Diabetic Nephropathy - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 214 pages

Ask Your Question

Diabetic Neuropathy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: